Verici Dx (Verici Dx) Other Income (Expense) : $-0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Other Income (Expense)?

Verici Dx's other income expense for the Verici Dx's pretax income for the six months ended in Jun. 2023 was $0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.00 Mil.

Verici Dx Other Income (Expense) Historical Data

The historical data trend for Verici Dx's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Other Income (Expense) Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Other Income (Expense)

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Other Income (Expense)	-	-	-	-	-

Verici Dx Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Verici Dx (OTCPK:VRCDF) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines